These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

329 related items for PubMed ID: 9429839

  • 1. A risk-benefit assessment of iron-chelation therapy.
    Porter JB.
    Drug Saf; 1997 Dec; 17(6):407-21. PubMed ID: 9429839
    [Abstract] [Full Text] [Related]

  • 2. Deferasirox for managing iron overload in people with thalassaemia.
    Bollig C, Schell LK, Rücker G, Allert R, Motschall E, Niemeyer CM, Bassler D, Meerpohl JJ.
    Cochrane Database Syst Rev; 2017 Aug 15; 8(8):CD007476. PubMed ID: 28809446
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).
    Kontoghiorghes GJ, Pattichi K, Hadjigavriel M, Kolnagou A.
    Transfus Sci; 2000 Dec 15; 23(3):211-23. PubMed ID: 11099897
    [Abstract] [Full Text] [Related]

  • 5. Oral deferiprone for iron chelation in people with thalassaemia.
    Fisher SA, Brunskill SJ, Doree C, Chowdhury O, Gooding S, Roberts DJ.
    Cochrane Database Syst Rev; 2013 Aug 21; (8):CD004839. PubMed ID: 23966105
    [Abstract] [Full Text] [Related]

  • 6. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
    Barman Balfour JA, Foster RH.
    Drugs; 1999 Sep 21; 58(3):553-78. PubMed ID: 10493280
    [Abstract] [Full Text] [Related]

  • 7. Oral deferiprone for iron chelation in people with thalassaemia.
    Roberts DJ, Brunskill SJ, Doree C, Williams S, Howard J, Hyde CJ.
    Cochrane Database Syst Rev; 2007 Jul 18; (3):CD004839. PubMed ID: 17636775
    [Abstract] [Full Text] [Related]

  • 8. Objectives and mechanism of iron chelation therapy.
    Hershko C, Link G, Konijn AM, Cabantchik ZI.
    Ann N Y Acad Sci; 2005 Jul 18; 1054():124-35. PubMed ID: 16339658
    [Abstract] [Full Text] [Related]

  • 9. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
    Taher A, Sheikh-Taha M, Koussa S, Inati A, Neeman R, Mourad F.
    Eur J Haematol; 2001 Jul 18; 67(1):30-4. PubMed ID: 11553264
    [Abstract] [Full Text] [Related]

  • 10. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Roberts DJ, Rees D, Howard J, Hyde C, Alderson P, Brunskill S.
    Cochrane Database Syst Rev; 2005 Oct 19; (4):CD004450. PubMed ID: 16235363
    [Abstract] [Full Text] [Related]

  • 11. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.
    Neufeld EJ.
    Blood; 2006 May 01; 107(9):3436-41. PubMed ID: 16627763
    [Abstract] [Full Text] [Related]

  • 12. Pharmacotherapy of iron overload in thalassaemic patients.
    Ceci A, Felisi M, De Sanctis V, De Mattia D.
    Expert Opin Pharmacother; 2003 Oct 01; 4(10):1763-74. PubMed ID: 14521486
    [Abstract] [Full Text] [Related]

  • 13. [Iron chelation in 1998].
    de Montalembert M.
    Transfus Clin Biol; 1998 Oct 01; 5(5):353-6. PubMed ID: 9836396
    [Abstract] [Full Text] [Related]

  • 14. Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.
    Kontoghiorghes GJ, Neocleous K, Kolnagou A.
    Drug Saf; 2003 Oct 01; 26(8):553-84. PubMed ID: 12825969
    [Abstract] [Full Text] [Related]

  • 15. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.
    Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Pibiri M, Nair SV, Walker JM, Pennell DJ.
    J Cardiovasc Magn Reson; 2008 Feb 25; 10(1):12. PubMed ID: 18298856
    [Abstract] [Full Text] [Related]

  • 16. Combined oral and parenteral iron chelation in beta thalassaemia major.
    Balveer K, Pyar K, Wonke B.
    Med J Malaysia; 2000 Dec 25; 55(4):493-7. PubMed ID: 11221163
    [Abstract] [Full Text] [Related]

  • 17. Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination.
    Kolnagou A, Kontoghiorghe CN, Kontoghiorghes GJ.
    Drug Res (Stuttg); 2017 Jul 25; 67(7):404-411. PubMed ID: 28320041
    [Abstract] [Full Text] [Related]

  • 18. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
    Hagag AA, Hamam MA, Taha OA, Hazaa SM.
    Infect Disord Drug Targets; 2015 Jul 25; 15(2):98-105. PubMed ID: 26205801
    [Abstract] [Full Text] [Related]

  • 19. Iron chelation therapy.
    Hoffbrand AV, Wonke B.
    J Intern Med Suppl; 1997 Jul 25; 740():37-41. PubMed ID: 9350180
    [Abstract] [Full Text] [Related]

  • 20. Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response.
    Aydinok Y, Evans P, Manz CY, Porter JB.
    Haematologica; 2012 Jun 25; 97(6):835-41. PubMed ID: 22180427
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.